A Phase 3 interventional study of Placebo and azelastineHcl in Seasonal Allergic Rhinitis, sponsored by Meda Pharmaceuticals. Completed at 45 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2013-06-24.
Sponsored by Meda Pharmaceuticals (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing azelastine in Rhinitis, Allergic, Seasonal — none open to participants now, none under way, none of them phase 3. azelastine · Rhinitis, Allergic, Seasonal.
Among the 16 studies testing azelastine in Rhinitis, Allergic, Seasonal, this one has the largest enrollment, is the only one that started in 2009, is one of 9 in phase 3, and was the 8th registered.
404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.
Browse Rhinitis, Allergic, Seasonal studies →None of the 16 studies testing azelastine in Rhinitis, Allergic, Seasonal is open now. The open studies under Rhinitis, Allergic, Seasonal, anywhere →
azelastine: first FDA approval 1996 (ASTELIN). What it is approved for, and how studies give it, is on its page →
Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,791 is above the median of 131 across 366 interventional studies indexed under Rhinitis, Allergic, Seasonal.
Median enrollment 415 across the 16 interventional studies. Of the 15 that completed or were terminated, 7 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 16 have an industry lead sponsor. The 8 most frequent:
This study is registered under Meda Pharmaceuticals, one of the names counted as Viatris Inc.. Under that name alone:
Meda Pharmaceuticals is the lead sponsor of 19 studies on the registry; none are open to participants now.
15 studies in Rhinitis, Allergic, Seasonal by Viatris Inc.: none open now, none under way, none of them phase 3. Of 15 finished, 10 (67%) have results posted.
Among the 15 studies in Rhinitis, Allergic, Seasonal by Viatris Inc., this one has the largest enrollment, is the only one that started in 2009, is one of 11 in phase 3, and was the 8th registered.
Viatris Inc.’s Rhinitis, Allergic, Seasonal studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 16 studies testing azelastine in Rhinitis, Allergic, Seasonal, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Viatris Inc.’s 15 in Rhinitis, Allergic, Seasonal:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if the combination of two allergy medications (formulated azelastine/fluticasone product)is more effective than placebo or either component medication alone (azelastine or fluticasone).
This will be a Phase III, randomized, double-blind, placebo-controlled, parallel-group study in subjects with moderate-to-severe seasonal allergic rhinitis (SAR). The study will begin with a 7-day, single-blind, placebo lead-in period (Day -7 to Day 1). Subjects will be instructed to take placebo lead-in medication twice daily (1 spray per nostril), approximately every 12 hours. On Day 1, subjects who satisfy the symptom severity requirements and continue to meet all of the study inclusion/exclusion criteria will be randomized in a 1:1:1:1 ratio to receive 1 spray per nostril twice daily of MP29-02, azelastine hydrochloride, fluticasone propionate, or placebo nasal spray.
Efficacy will be assessed by the change from baseline in the subject-reported 12-hour reflective Total Nasal Symptom Score (TNSS). On Days 1 through 14, subjects will rate the instantaneous and reflective TNSS symptoms of sneezing, nasal congestion, runny nose, and nasal itching; the instantaneous and reflective total ocular symptom score (TOSS) symptoms of itchy eyes, watery eyes and eye redness; the symptom of postnasal drip will be reflectively, twice daily (AM and PM) in a diary prior to the dose of study medication. Symptoms will be scored on a 0 to 3 scale (0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms, 3 = severe symptoms), such that the maximum daily symptom severity score will be 24 for the TNSS and 18 for the TOSS. Additional secondary efficacy variables will include reflective individual nasal and ocular symptom scores, as well as change from Baseline to Day 14 in the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ).
Subjects ≥ 18 years of age will complete the RQLQ on Day 1 (prior to dosing) and Day 14. Subjects will return to the clinic on Day 7 for an interim evaluation. After completing the 2-week double-blind treatment period, subjects will return to the clinic on Day 14 (or at time of early termination) for an end-of-study evaluation. Safety and tolerability assessments will be made on Days 7 and 14. Tolerability will be evaluated by subject-reported adverse events (AEs), nasal examinations, and vital signs assessments
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must have moderate-to-severe rhinitis, with one or more of the following present:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo
Drug: azelastineHcl
Drug: fluticasone propionate
Drug: azelastine Hcl/fluticasone propionate
Placebo
azelastine hydrochloride 548 mg
Also known as: astelin
fluticasone propionate 200 mcg
Drug pages: Azelastine · Fluticasone
azelastine hydrochloride 548 mcg/fluticasone propionate 200 mcg
Also known as: MP29-02
Change From Baseline in 12 Hour Reflective Total Nasal Symptom Score (rTNSS)
change from baseline in 12-hour reflective total nasal symptom score (rTNSS)consisting of nasal congestion,runny nose, itchy nose and sneezing scored twice daily (AM and PM) in diary cards for the entire 14 day study period.The measurement scale is 0 to 24.A reduction in symptom severity score is indicated by a negative value.An greater negative value is suggestive of improvement.
Time frame: day 1 to day 14
Change From Baseline in 12 Hour Instantaneous Total Nasal Symptom Score (iTNSS)
change from baseline in 12-hour instantaneous total nasal symptom score (iTNSS)consisting of nasal congestion,runny nose, itchy nose and sneezing scored twice daily (AM and PM) in diary cards for the entire 14 day study period.The measurement scale is 0 to 24.A reduction in symptom severity score is indicated by a negative value.A greater negative score is suggestive of improved condition.
Time frame: day 1 to day 14
Change From Baseline in Adult Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)
adult Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scored at day 1(baseline) and at day 14.The scale is measured from a value of 0 to 24. A negative number corresponds to a change from baseline measurement. An increased negative number is suggestive of improvement.
Time frame: day 1 to day 14
| Milestone | MP29-02 | Azelastine Hcl | Fluticasone Propionate | Placebo |
|---|---|---|---|---|
| Started | 448 | 445 | 450 | 448 |
| Completed | 434 | 430 | 431 | 433 |
| Not completed | 14 | 15 | 19 | 15 |
change from baseline in 12-hour reflective total nasal symptom score (rTNSS)consisting of nasal congestion,runny nose, itchy nose and sneezing scored twice daily (AM and PM) in diary cards for the entire 14 day study period.The measurement scale is 0 to 24.A reduction in symptom severity score is indicated by a negative value.An greater negative value is suggestive of improvement.
| units on a scale | MP29-02 | Azelastine Hcl | Fluticasone Propionate | Placebo |
|---|---|---|---|---|
| Change From Baseline in 12 Hour Reflective Total Nasal Symptom Score (rTNSS) | -5.5 ± 5.2 | -4.8 ± 4.8 | -4.9 ± 4.7 | -3.4 ± 4.3 |
change from baseline in 12-hour instantaneous total nasal symptom score (iTNSS)consisting of nasal congestion,runny nose, itchy nose and sneezing scored twice daily (AM and PM) in diary cards for the entire 14 day study period.The measurement scale is 0 to 24.A reduction in symptom severity score is indicated by a negative value.A greater negative score is suggestive of improved condition.
| units on a scale | MP29-02 | Azelastine Hcl | Fluticasone Propionate | Placebo |
|---|---|---|---|---|
| Change From Baseline in 12 Hour Instantaneous Total Nasal Symptom Score (iTNSS) | -5.0 ± 5.3 | -4.3 ± 4.9 | -4.7 ± 4.9 | -3.1 ± 4.4 |
adult Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scored at day 1(baseline) and at day 14.The scale is measured from a value of 0 to 24. A negative number corresponds to a change from baseline measurement. An increased negative number is suggestive of improvement.
| units on a scale | MP29-02 | Azelastine Hcl | Fluticasone Propionate | Placebo |
|---|---|---|---|---|
| Change From Baseline in Adult Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) | -1.6 ± 1.3 | -1.4 ± 1.3 | -1.6 ± 1.2 | -1.0 ± 1.2 |
Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MP29-02 | — | 1/448 (0.2%) | 57/448 (12.7%) |
| Azelastine Hcl | — | 0/449 (0%) | 47/449 (10.5%) |
| Fluticasone Propionate | — | 0/450 (0%) | 32/450 (7.1%) |
| Placebo | — | 1/451 (0.2%) | 26/451 (5.8%) |
| Event | MP29-02 | Azelastine Hcl | Fluticasone Propionate | Placebo |
|---|---|---|---|---|
| lacerated right handInjury, poisoning and procedural complications | 1/448 | 0/449 | 0/450 | 0/451 |
| pyogenic arthritis right elbowInfections and infestations | 0/448 | 0/449 | 0/450 | 1/451 |
| Event | MP29-02 | Azelastine Hcl | Fluticasone Propionate | Placebo |
|---|---|---|---|---|
| dysgusiaGastrointestinal disorders | 21/448 | 23/449 | 1/450 | 0/451 |
| headacheNervous system disorders | 10/448 | 14/449 | 8/450 | 4/451 |
| epistaxisRespiratory, thoracic and mediastinal disorders | 10/448 | 6/449 | 6/450 | 8/451 |
| oropharyngial painGeneral disorders | 5/448 | 2/449 | 6/450 | 2/451 |
| somnolenceNervous system disorders | 5/448 | 2/449 | 0/450 | 1/451 |
| mucosal erosionRespiratory, thoracic and mediastinal disorders | 2/448 | 0/449 | 5/450 | 1/451 |
| nasopharyngitisInfections and infestations | 3/448 | 0/449 | 3/450 | 5/451 |
| sinus headacheNervous system disorders | 1/448 | 0/449 | 3/450 | 5/451 |
| Age, Categorical(Participants) | MP29-02 | Azelastine Hcl | Fluticasone Propionate | Placebo | Total |
|---|---|---|---|---|---|
| <=18 years | 57 | 38 | 56 | 46 | 197 |
| Between 18 and 65 years | 382 | 390 | 390 | 387 | 1549 |
| >=65 years | 9 | 17 | 4 | 15 | 45 |
| Age Continuous(years) | MP29-02 | Azelastine Hcl | Fluticasone Propionate | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 35.6 ± 14.5 | 36.4 ± 14.8 | 34.2 ± 14.5 | 34.7 ± 14.1 | 35.2 ± 14.5 |
| Sex: Female, Male(Participants) | MP29-02 | Azelastine Hcl | Fluticasone Propionate | Placebo | Total |
|---|---|---|---|---|---|
| Female | 277 | 271 | 280 | 269 | 1097 |
| Male | 171 | 174 | 170 | 179 | 694 |
| Region of Enrollment(participants) | MP29-02 | Azelastine Hcl | Fluticasone Propionate | Placebo | Total |
|---|---|---|---|---|---|
| United States | 448 | 445 | 450 | 448 | 1791 |
The record gives a start of Apr 2009, a primary completion of Jul 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2012, 3 years 2 months after primary completion. A results delay was requested in Jun 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Azelastine · Fluticasone
Rhinitis, Allergic, Seasonal →